|Articles|July 31, 2009
Covance Becomes First CRO to Globally Deliver Innovative Technique for TK/PK Sampling
Advertisement
PRINCETON, NJ-July 31, 2009
"As the first CRO to globally support the DBS sample technique, this integrated service provides more efficient toxicology and bioanalytical testing to potentially improve data quality," said Steven Michael, vice president and chief scientific officer, global bioanalytical services, Covance. "This service reduces sample volumes, provides a more refined sample collection process, and improved data quality to increase study speed and quality. Covance spent more than a year analyzing thousands of DBS samples from multiple studies to perfect the bioanalytical technique."
The DBS sampling technique increases sample handling safety with chemically treated cards that inactivate HIV and Hepatitis B. The technique also enhances compound stability and increases flexibility in study design while providing convenient collection, shipping, and storage of blood samples for toxicokinetic and pharmacokinetic data. DBS also offers clinical advantages as a preferred method of blood collection over venous cannula sampling.
"This new service provides our clients with sound ethical and cost benefits by significantly reducing sample volumes and improving data quality," said Steve Barkyoumb, vice president, North America toxicology, Covance.
About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 10,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained via
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
2
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
3
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
4